Search clinical trials for: rituximab

Total 2316 results

National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma

Stage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell Lymphoma | Stage I Mantle Cell Lymphoma

United States
Uprety Shraddha
Postgraduate Institute of Medical Education and Research

Unknown

Comparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in Severe Pemphigus

Pemphigus

India
PETHEMA Foundation

Completed

Rituximab Combined With Chemotherapy in Burkitt's Lymphoma

Acute Lymphoblastic Leukemia | Burkitt's Lymphoma

Spain
Gilead Sciences

Approved for marketing

Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia (CLL)

United States, Italy, United Kingdom, Ireland
Massachusetts General Hospital
Novartis; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center

Completed

Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma

Diffuse Large B-cell Lymphoma

United States
Sanofi

Terminated

Evaluation of Inflammatory Symptoms Reduction With Amoxicillin + Ketoprofen in Acute Pharyngeal Tonsillitis in Pediatric Patients (DROPS)

Pharyngotonsillitis

Brazil
Yale University
Celgene Corporation

Terminated

Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Oslo University Hospital
Norwegian Cancer Society; Helse Sor-Ost

Completed

Phase II Cancer Vaccine Trial for Patients With Follicular Lymphoma (Lymvac-1)

Follicular Lymphoma

Norway
Hoffmann-La Roche

Completed

A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

Idiopathic Thrombocytopenic Purpura

Italy
M.D. Anderson Cancer Center

Completed

FM 140 vs FM100 Study in Patients With Multiple Myeloma

Multiple Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura

Nonneoplastic Condition

United States
National Cancer Institute (NCI)

Terminated

Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma

Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Lymphoblastic Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone... and other conditions

United States
Nordic Lymphoma Group
Amgen

Completed

Dose Dense Chemotherapy and Rituximab for Young High Risk Diffuse Large B-Cell Lymphoma Patients (CRY-04) (CRY-04)

Diffuse Large B-Cell Lymphoma

Norway, Denmark, Finland, Sweden
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma

Childhood Diffuse Large Cell Lymphoma | Childhood Immunoblastic Large Cell Lymphoma | Childhood Burkitt Lymphoma | Untreated Childhood Acute Lymphoblastic Leukemia | Stage I Childhood Large Cell Lymphoma | Stage I Childhood Small Noncleaved Cell Lymphoma | Stage II Childhood Large Cell Lymphoma | Stage II Childhood Small Noncleaved Cell Lymphoma and other conditions

United States
Northern Italy Leukemia Group

Completed

Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma

Burkitt Lymphoma | B-ALL

Italy
Hoffmann-La Roche

Completed

SMART Study: A Study of Re-treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on Anti-TNF Alfa Therapy

Rheumatoid Arthritis

France
Stanford University

Completed

Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma

Lymphoma | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Diffuse Large Cell Lymphoma | Transformed Lymphoma | Other Subtypes of B-cell Lymphoma

United States
M.D. Anderson Cancer Center
Biogen

Completed

Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma

Lymphoma

United States
Hoffmann-La Roche
Nordic Lymphoma Group

Completed

A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Lymphoma

Sweden, Denmark, Norway
University Hospital, Rouen

Completed

Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid (Rituximab2)

Bullous Pemphigoid

France
Haukeland University Hospital

Completed

B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome

Chronic Fatigue Syndrome | Myalgic Encephalomyelitis

Norway
Fudan University

Terminated

Dose-adjusted EPOCH-R in MYC Positive DLBCL

Diffuse Large B-cell Lymphoma

China
Hoffmann-La Roche

Completed

GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

Belgium, Italy, Spain, United States, Canada, Sweden, Greece, Netherlands, Austria, Switzerland, Poland, Turkey, Croatia, Brazil, Argentina, Denmark, United Kingdom
Emory University
Celgene Corporation

Terminated

A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)

Leukemia, Lymphocytic, Chronic, B-Cell | Chronic Lymphocytic Leukemia | Lymphoma, Small Lymphocytic

United States
Hospices Civils de Lyon

Completed

A Study of Two Associations of Rituximab and Chemotherapy, With a PET-driven Strategy, in Lymphoma (LNH2007-3B)

Lymphoma, B-Cell | Lymphoma, Large-Cell, Diffuse

France
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Terminated

Rituximab and GM-CSF in Treating Patients With Chronic Lymphocytic Leukemia

Leukemia
Hoffmann-La Roche

Terminated

A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.

Lymphoma

Canada
Hoffmann-La Roche

Completed

A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Agents.

Rheumatoid Arthritis

Taiwan
Pharmacyclics LLC.

Completed

Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)

B-cell Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S8809-S9800-S9911-S9704-A Study of Blood and Tissue Samples From Patients With Follicular Lymphoma Treated With Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone

Lymphoma
Celltrion

Terminated

Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence Trial (Triad-DLBCL)

Diffuse Large B-Cell Lymphoma

Korea, Republic of
Roswell Park Cancer Institute
Ortho Biotech, Inc.

Terminated

Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment

Lymphoma

United States
Hoffmann-La Roche

Terminated

A Pharmacokinetic and Pharmacodynamic Study of MabThera (Rituximab) Plus Methotrexate in Patients With Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

Netherlands
Bayer
RTI Health Solutions

Completed

Risk of Acute Liver Injury in Users of Antimicrobials

Drug-Induced Liver Injury

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Lymphoma | Leukemia

United States
Oncology Specialists, S.C.

Completed

Non-Hodgkin Lymphoma in Elderly Patients Above the Age of 80 in the Rituximab Era

Non-Hodgkin's Lymphoma
Hoffmann-La Roche

Completed

A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate

Rheumatoid Arthritis

Morocco
Czech CLL Study Group

Unknown

Observational Study of Low Dose FCR in Elderly/Comorbid CLL/SLL: The Q-lite Project (Q-lite)

Chronic Lymphocytic Leukemia

Czech Republic
Jurgen Barth

Completed

Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab

Hairy Cell Leukemia (HCL)

Germany
H. Lee Moffitt Cancer Center and Research Institute

Completed

Phase II Trial of Pentostatin and Targeted Busulfan (Pento & tBU)

Hematologic Malignancies

United States
Steven P. Treon, MD, PhD
Massachusetts General Hospital; Dana-Farber Cancer Institute; Beth Israel Deaconess... and other collaborators

Completed

Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia

Lymphoplasmacytic Lymphoma | Waldenstrom's Macroglobulinemia

United States
National Cancer Institute (NCI)

Completed

Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
University of Southern California

Terminated

Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas

Non-Hodgkin's Lymphoma | Burkitt Lymphoma | Primary Effusion Lymphomas

United States
University of Southern California

Terminated

Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
National Cancer Institute (NCI)

Completed

Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma

Stage III Adult Diffuse Large Cell Lymphoma | Stage IV Adult Diffuse Large Cell Lymphoma | Contiguous Stage II Adult Diffuse Large Cell Lymphoma | Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma

United States
National Cancer Institute (NCI)

Completed

Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States
California Cancer Assocaties for Research & Excellence

Unknown

Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma

Metastatic Melanoma | Malignant Melanoma of Skin Stage III

United States
Ruijin Hospital

Completed

Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

China
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

AIDS-related Peripheral/Systemic Lymphoma | AIDS-related Diffuse Large Cell Lymphoma | AIDS-related Immunoblastic Large Cell Lymphoma | AIDS-related Small Noncleaved Cell Lymphoma

United States
Genzyme, a Sanofi Company

Completed

An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease

Glycogen Storage Disease Type II | Pompe Disease

United States

Search clinical trials for: rituximab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations